Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.

@article{Creutzig2008SignificanceOA,
  title={Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.},
  author={Ursula Creutzig and Thomas B{\"u}chner and Maria Cristina Sauerland and Martin Zimmermann and Dirk Reinhardt and Hartmut D{\"o}hner and Richard F Schlenk},
  journal={Cancer},
  year={2008},
  volume={112 3},
  pages={562-71}
}
BACKGROUND Data on the impact of age in acute myeloid leukemia (AML) patients <30 years treated in pediatric and adult trials are scarce. METHODS In all, 891 patients <18 years were treated in the pediatric trials AML-BFM 93/98 and 290 adolescents and young adults (>16 to <30 years) in the AMLCG 92/99 and AMLSG HD93/98A trials. Treatment schedules and dose intensities were comparable. RESULTS Initial features and risk factors differed considerably between infants (<2 years) and older age… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…